These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 26711933)

  • 41. Resected pN1 non-small cell lung cancer: recurrence patterns and nodal risk factors may suggest selection criteria for post-operative radiotherapy.
    Borghetti P; Barbera F; Bonù ML; Trevisan F; Ciccarelli S; Vitali P; Maddalo M; Triggiani L; Pasinetti N; Pedretti S; Bonetti B; Pariscenti G; Tironi A; Caprioli A; Buglione M; Magrini SM
    Radiol Med; 2016 Sep; 121(9):696-703. PubMed ID: 27230669
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.
    Rosenzweig KE; Fox JL; Yorke E; Amols H; Jackson A; Rusch V; Kris MG; Ling CC; Leibel SA
    Cancer; 2005 May; 103(10):2118-27. PubMed ID: 15830346
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
    Bradley JD; Paulus R; Graham MV; Ettinger DS; Johnstone DW; Pilepich MV; Machtay M; Komaki R; Atkins J; Curran WJ;
    J Clin Oncol; 2005 May; 23(15):3480-7. PubMed ID: 15908657
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
    Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
    J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Postoperative radiotherapy for incompletely resected non-small cell lung cancer: clinical outcomes and prognostic value of the histological subtype.
    Ohguri T; Yahara K; Moon SD; Yamaguchi S; Imada H; Hanagiri T; Tanaka F; Terashima H; Korogi Y
    J Radiat Res; 2012; 53(2):319-25. PubMed ID: 22327172
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Changes of circulating transforming growth factor-beta1 level during radiation therapy are correlated with the prognosis of locally advanced non-small cell lung cancer.
    Zhao L; Ji W; Zhang L; Ou G; Feng Q; Zhou Z; Lei M; Yang W; Wang L
    J Thorac Oncol; 2010 Apr; 5(4):521-5. PubMed ID: 20130485
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up.
    Agolli L; Valeriani M; Bracci S; Nicosia L; DE Sanctis V; Enrici RM; Osti MF
    Anticancer Res; 2015 Oct; 35(10):5693-700. PubMed ID: 26408745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of adjuvant treatment for microscopic residual disease after non-small cell lung cancer surgery.
    Hancock JG; Rosen JE; Antonicelli A; Moreno A; Kim AW; Detterbeck FC; Boffa DJ
    Ann Thorac Surg; 2015 Feb; 99(2):406-13. PubMed ID: 25528723
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis.
    Kim BH; Kim HJ; Wu HG; Kang CH; Kim YT; Lee SH; Kim DW
    Clin Lung Cancer; 2014 Sep; 15(5):356-64. PubMed ID: 24996882
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
    Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
    Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is survival following post-operative radiotherapy in pN1-non-small cell lung cancer reduced? Results of a multivariate analysis.
    Willner J; Wiens V; Jachmann M; Haubitz I; Flentje M
    Oncol Rep; 2004 Sep; 12(3):647-53. PubMed ID: 15289850
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of outcomes for patients with medically inoperable Stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy.
    Fang LC; Komaki R; Allen P; Guerrero T; Mohan R; Cox JD
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):108-16. PubMed ID: 16904517
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study.
    Kong FM; Ten Haken RK; Schipper MJ; Sullivan MA; Chen M; Lopez C; Kalemkerian GP; Hayman JA
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):324-33. PubMed ID: 16168827
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non-Small-Cell Lung Cancer.
    Francis S; Orton A; Stoddard G; Tao R; Hitchcock YJ; Akerley W; Kokeny KE
    J Clin Oncol; 2018 Feb; 36(4):333-341. PubMed ID: 29236592
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
    Yang H; Wang K; Li S; Li Y; Yuan L
    Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
    [No Abstract]   [Full Text] [Related]  

  • 56. Prognostic value of gross tumor volume for definitive radiation therapy in patients with locoregionally recurrent non-small-cell lung cancer after surgical resection.
    Lee NK; Moon SH; Kim TH; Han JY; Yun T; Kim HT; Lee HS; Kim MS; Lee JM; Cho KH; Lee JS
    Clin Lung Cancer; 2013 Jul; 14(4):399-406. PubMed ID: 23276823
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
    Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Trends in Postoperative Intensity-Modulated Radiation Therapy Use and Its Association With Survival Among Patients With Incompletely Resected Non-Small Cell Lung Cancer.
    Yu B; Jun Ma S; Waldman O; Dunne-Jaffe C; Chatterjee U; Turecki L; Gill J; Yendamuri K; Iovoli A; Farrugia M; Singh AK
    JAMA Netw Open; 2022 Sep; 5(9):e2230704. PubMed ID: 36074462
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma.
    Machtay M; Lee JH; Shrager JB; Kaiser LR; Glatstein E
    J Clin Oncol; 2001 Oct; 19(19):3912-7. PubMed ID: 11579111
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.